Table 1 Patient access schemes in the Asia-Pacific region by country, type and condition
From: Patient access schemes in Asia-pacific markets: current experience and future potential
Australia | South Korea | New Zealand | Total | |
|---|---|---|---|---|
Types | ||||
Outcome-based | 21 | - | - | 21 |
Evidence generation | 3 | - | - | 3 |
Financially-based | 33 | 3 | 5 | 41 |
Hybrid* | 41 | - | - | 41 |
Conditions | ||||
Cancer | 29 | - | 2 | 31 |
Inflammatory Conditions | 28 | - | 1 | 29 |
Infectious Disease | 7 | - | - | 7 |
Pulmonary Hypertension | 7 | 1 | 1 | 9 |
Other | 27 | 2 | 1 | 30 |
Technology | ||||
Pharmaceuticals | 95 | 3 | 5 | 103 |
Medical devices | 3 | - | - | 3 |
Subtotal | 98 | 3 | 5 | 106 |